samedan logo
 
 
 
spacer
home > ebr > autumn 2019 > the advantages of long-read sequencing
PUBLICATIONS
European Biopharmaceutical Review

The Advantages of Long-Read Sequencing




DNA sequencing technologies have contributed to drug discovery and development pipelines for decades, but more recent innovations offer to significantly expand the applications for which sequencing is an appropriate choice.

While next-generation sequencing (NGS) instruments were essential for making sequencing more affordable, the short reads they produce are not universally useful. They have been excellent for applications such as genotyping or discovering single nucleotide variants associated with disease. However, for many applications, scientists need reads long enough to span whole genes or complex genomic elements such as disease-causing repeat expansions or structural variants.

Improvements in long-read sequencing technology have addressed this unmet need. Single-molecule, real-time (SMRT) sequencing can produce reads that are tens of thousands of bases long, allowing for complete coverage of large amplicons or genomic elements, alternative splicing isoforms, and more.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jonas Korlach PhD is Chief Scientific Officer of Pacific Biosciences. He is the recipient of multiple grants, an inventor on 70 issued US patents and 61 international patents, and an author of more than 100 scientific studies on the principles and applications of SMRT technology, including publications in Nature, Science, and PNAS. He received both his PhD and his MS degrees in Biochemistry, Molecular and Cell Biology from Cornell University, and received MS and BA degrees in Biological Sciences from Humboldt University in Berlin.
spacer
Jonas Korlach
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Biognosys Announces the Launch of its Next-Generation Plasma Biomarker Discovery Solution

October 5th, 2021 SCHLIEREN, (Zurich, Switzerland). Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, today announces the upcoming launch of its next-generation plasma biomarker discovery solution.
More info >>

White Papers

Managing GxP Environmental Systems to Ensure Data Integrity

Vaisala Ltd


More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement